CAL
HRMY icon

Capital Analysts LLC’s Harmony Biosciences HRMY Stock Holding History

Capital Analysts LLC’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$3K – 767
2020
Q3 		$3K Buy
+100
New +$3.65K ﹤0.01% 686

Other funds holding HRMY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Analysts LLC's HRMY Position: Q4 2020 in Review

Capital Analysts LLC sold out of Harmony Biosciences (HRMY) in Q4 2020, closing a stake of 100 shares — an estimated $3K sold.

Capital Analysts LLC first reported a position in HRMY in Q3 2020 and held it in 1 quarter. The position peaked at $3K in Q3 2020. 59 funds tracked by Wall St. Rank hold HRMY as of Q4 2020.

  • Capital Analysts LLC reported no remaining Harmony Biosciences position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 100 Harmony Biosciences shares in Q4 2020, an estimated $3K.
  • Capital Analysts LLC first reported a position in Harmony Biosciences in Q3 2020 and held it in 1 quarter.
  • Capital Analysts LLC's Harmony Biosciences position peaked at $3K in Q3 2020.
  • 59 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.